NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (2) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (2)
EP (6) EP1880735A3 (2)
JP (4) JP4846906B2 (2)
KR (3) KR100798212B1 (2)
CN (3) CN100339130C (2)
AR (3) AR022965A1 (2)
AT (3) ATE459373T1 (2)
AU (3) AU750762B2 (2)
BE (1) BE1025464I2 (2)
BR (4) BRPI0009163B8 (2)
CA (3) CA2366152A1 (2)
CY (3) CY1107561T1 (2)
CZ (3) CZ301445B6 (2)
DE (4) DE60043930D1 (2)
DK (2) DK1163000T3 (2)
ES (3) ES2275499T3 (2)
FR (1) FR10C0008I2 (2)
HK (3) HK1043730A1 (2)
HU (4) HU228499B1 (2)
IL (5) IL145043A0 (2)
LU (1) LU91652I2 (2)
MX (1) MXPA01009452A (2)
MY (2) MY125202A (2)
NL (1) NL300415I1 (2)
NO (4) NO20014322L (2)
NZ (3) NZ513841A (2)
PL (3) PL203917B1 (2)
PT (2) PT1163000E (2)
SI (2) SI1162999T1 (2)
TR (3) TR200102735T2 (2)
TW (3) TWI286938B (2)
WO (3) WO2000056359A2 (2)

Families Citing this family (290)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composiƧƵes para utilizaĆ§Ć£o na induĆ§Ć£o da imunidade mucosal
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
OA12590A (en) * 2001-01-23 2006-06-08 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine.
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CN100515494C (zh) 2001-12-12 2009-07-22 åÆé¾™ęœ‰é™å…¬åø ęŠ—ę²™ēœ¼č”£åŽŸä½“ēš„免ē–«
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
WO2004035618A2 (en) * 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra mĆŗltiples serogrupos de meningococos
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarĆ­deo-proteĆ­na veĆ­culo adesina da superfĆ­cie estafilocĆ³cica para imunizaĆ§Ć£o contra infecƧƵes nosocomiais
KR101052996B1 (ko) * 2003-03-13 2011-07-29 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė°•ķ…Œė¦¬ģ•„ ģ„øķ¬ģš©ķ•“ģ†Œģ— ėŒ€ķ•œ ģ •ģ œ ź³µģ •
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
EP1631264B8 (en) 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
CN103357002A (zh) 2003-10-02 2013-10-23 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™å…¬åø 多ē§č„‘č†œē‚ŽēƒčŒč”€ęø…ē¾¤ēš„ę¶²ä½“ē–«č‹—
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
ATE512670T1 (de) 2004-04-30 2011-07-15 Novartis Vaccines & Diagnostic Meningokokken-konjugat-impfung
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
JP2008504292A (ja) 2004-06-24 2008-02-14 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ 免ē–«å¢—å¼·ē”Øć®åŒ–åˆē‰©
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesĆ­culas basadas en GNA1870 para protecciĆ³n de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CA2604363C (en) * 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2008536515A (ja) 2005-04-18 2008-09-11 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ćƒÆć‚Æćƒćƒ³ć®čŖæč£½ć®ćŸć‚ć®ļ½‚åž‹č‚ē‚Žć‚¦ć‚¤ćƒ«ć‚¹č”Øé¢ęŠ—åŽŸć®ē™ŗē¾
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
NZ598367A (en) 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
AU2007206114B2 (en) * 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
AU2007227504B2 (en) * 2006-03-17 2013-10-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
PE20080774A1 (es) * 2006-03-30 2008-08-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhƦsiner
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
PT2074221E (pt) * 2006-10-10 2010-09-06 Wyeth Llc MĆ©todos melhorados para a separaĆ§Ć£o de polissacĆ”ridos tipo 3 de streptococcus pneumoniae
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
SI2167121T1 (sl) * 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
AU2009208403A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
CN102356089B (zh) 2008-02-21 2014-02-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒfHBPå¤šč‚½
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland ProteĆ­nas quimĆ©ricas de uniĆ³n al factor H (fHBP) que contienen un dominio B heterĆ³logo, y mĆ©todos de uso
KR20110031393A (ko) 2008-07-21 2011-03-25 ė” ėøŒė¦¬ź²€ ģ•¤ė“œ ģš°ėؼģ¦ˆ ķ•˜ģŠ¤ķ”¼ķ„ø, ģøķ¬. ķ•©ģ„± ė² ķƒ€-1,6 źø€ė£Øģ½”ģ‚¬ėƼ ģ˜¬ė¦¬ź³ ė‹¹ģ— ź“€ķ•œ ė°©ė²• ė° ģ”°ģ„±ė¬¼
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiŔčenja za ogljikohidrat iz Streptococcus skupine A
KR101413844B1 (ko) 2008-12-09 2014-06-30 ķ™”ģ“ģž ė°±ģ‹ ģŠ¤ ģ—˜ģ—˜ģ”Ø ļ¼©ļ½‡ļ¼„ ļ¼£ļ¼Øļ¼“ ķŽ©ķ‹°ė“œ ė°±ģ‹ 
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
JP2012512240A (ja) 2008-12-17 2012-05-31 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒ˜ćƒ¢ć‚°ćƒ­ćƒ“ćƒ³å—å®¹ä½“ć‚’å«ć‚€é«„č†œē‚ŽčŒćƒÆć‚Æćƒćƒ³
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CN102481349B (zh) 2009-01-12 2014-10-15 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—é©å…°ę°é˜³ę€§ē»†čŒē–«č‹—äø­ēš„Cna_Bē»“ęž„åŸŸ
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa AdjuvĆ”lĆ³ H meningococcus faktort kƶtƵ fehĆ©rje
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogĆŖnicos de polissacarĆ­deo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composiƧƵes que os compreendem
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigƩnek immunogƩn kƩszƭtmƩnyei
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
PE20161551A1 (es) * 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
CN102695523A (zh) 2009-09-10 2012-09-26 čÆŗåŽęœ‰é™å…¬åø 针åƹ呼åø道ē–¾ē—…ēš„ē»„合ē–«č‹—
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificaĆ§Ć£o de staphylococcus aureus tipo 5 e tipo 8 sacarĆ­deos capsulares
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX2012006961A (es) * 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
US20130034573A1 (en) 2009-12-22 2013-02-07 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland ProteĆ­nas de uniĆ³n al factor H (fHbp) con propiedades alteradas y mĆ©todos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US20110287048A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen Specific Tregs and related compositions, methods and systems
KR20130121699A (ko) 2010-05-28 2013-11-06 ķ…ŒķŠøė¦¬ģŠ¤ ģ˜Øė¼ģø, ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģƒķ˜øģž‘ģš© ķ˜¼ģ„± ė¹„ė™źø° ģ»“ķ“Øķ„° ź²Œģž„ źø°ė°˜źµ¬ģ”°
PT2575870T (pt) * 2010-06-04 2017-02-10 Wyeth Llc FormulaƧƵes de vacinas
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 ķŽ˜ķŠøė„“ ģ  ė‚˜ė””ģ—ė¹„ģ¹˜ ģ•„ķŒŒė¦° ģ‹œź²”ė¼ ģ†Œė„¤ģ“ ė°•ķ…Œė¦¬ģ•„ģ˜ ģ„øķ¬ģ™ø ė‹¤ė‹¹ė„˜, ģ“ė„¼ ģ œģ”°ķ•˜ėŠ” ė°©ė²•, ģ“ė„¼ ķ•Øģœ ķ•œ ė°±ģ‹  ė° ģ•½ģ œ ģ”°ģ„±ė¬¼
CN107837394A (zh) 2011-06-24 2018-03-27 埃ēš®ę‰˜å‰å°¼č„æę–Æęœ‰é™å…¬åø 作äøŗęŠ—åŽŸē‰¹å¼‚ę€§å…ē–«č°ƒčŠ‚剂ēš„åŒ…å«é€‰ę‹©ēš„č½½ä½“ć€ē»“ē”Ÿē“ ć€å•å®å’Œē±»é»„é…®ēš„ē»„合ēš„čÆē‰©ē»„合ē‰©
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
RU2014138418A (ru) 2012-02-24 2016-04-10 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ Š‘ŠµŠ»ŠŗŠø ŠæŠøŠ»ŠµŠ¹ Šø ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
JP2015510872A (ja) 2012-03-07 2015-04-13 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½Žļ½…ļ½•ļ½ļ½ļ½Žļ½‰ļ½ļ½…ęŠ—åŽŸć®å¢—å¼·ć•ć‚ŒćŸč£½å‰¤
CN104159603A (zh) 2012-03-08 2014-11-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åø¦ęœ‰tlr4ęæ€åŠØ剂ēš„č”åˆē–«č‹—
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
CN104321078A (zh) 2012-04-26 2015-01-28 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—åŽŸå’ŒęŠ—åŽŸē»„合
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
US20150273036A1 (en) 2012-10-12 2015-10-01 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
JP2015534964A (ja) * 2012-10-17 2015-12-07 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
JP6411378B2 (ja) 2013-02-01 2018-10-24 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ļ¼“ļ½ļ½Œļ½Œę§˜å—å®¹ä½“ć‚¢ć‚“ćƒ‹ć‚¹ćƒˆć‚’å«ć‚€å…ē–«å­¦ēš„ēµ„ęˆē‰©ć®ēš®å†…送達
JP2016521284A (ja) 2013-05-10 2016-07-21 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 大č…øć‚¬ćƒ³ć®ćƒ—ćƒ­ćƒć‚¤ć‚Ŗćƒ†ć‚£ć‚Æć‚¹ć«ć‚ˆć‚‹é˜²ę­¢ćŠć‚ˆć³å‡¦ē½®
JP2016520077A (ja) 2013-05-15 2016-07-11 悶 ć‚¬ćƒćƒŠćƒ¼ć‚ŗ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ć‚¢ćƒ«ćƒćƒ¼ć‚æ ļ¼„ļ¼‘ļ½…ļ¼’ļ½ˆļ½ƒļ½–ćƒÆć‚Æćƒćƒ³åŠć³ä½æē”Øę–¹ę³•
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
RU2662968C2 (ru) 2013-09-08 2018-07-31 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя ŠæрŠ¾Ń‚ŠøŠ² neisseria meningitidis (Š²Š°Ń€ŠøŠ°Š½Ń‚Ń‹)
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN120718167A (zh) 2014-01-21 2025-09-30 č¾‰ē‘žå¤§čÆ厂 č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–及其ē¼€åˆē‰©
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
JP6786394B2 (ja) 2014-02-28 2020-11-18 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ę”¹å¤‰é«„č†œē‚ŽčŒļ½†ļ¼Øļ½‚ļ½ćƒćƒŖ惚惗惁惉
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
CN107427568B (zh) 2015-01-15 2021-12-14 č¾‰ē‘žå…¬åø ē”ØäŗŽč‚ŗē‚ŽēƒčŒē–«č‹—äø­ēš„免ē–«åŽŸę€§ē»„合ē‰©
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
JP2018522885A (ja) 2015-07-07 2018-08-16 ć‚¢ćƒ•ć‚£ćƒŖć‚¹ćƒ»ć‚¢ć‚Æćƒć‚§ćƒ³ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆļ¼”ļ½†ļ½†ļ½‰ļ½’ļ½‰ļ½“ ļ¼”ļ½‡ ļ¼©ļ½‡ļ¼„介åœØꀧē–¾ę‚£ć®å‡¦ē½®ćŠć‚ˆć³äŗˆé˜²ć®ćŸć‚ć®ćƒÆć‚Æćƒćƒ³
CN108367063A (zh) 2015-07-21 2018-08-03 č¾‰ē‘žå…¬åø 包含ē¼€åˆēš„čšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶čƕ剂ē›’å’Œē”Ø途
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
CA3000313A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ č‚ŗē‚Žé€£éŽ–ēƒčŒćƒÆć‚Æćƒćƒ³ć«ćŠć„ć¦ē”Øć„ć‚‹ćŸć‚ć®å…ē–«åŽŸę€§ēµ„ęˆē‰©
KR20180088458A (ko) 2015-12-04 2018-08-03 ė‹¤ė‚˜-ķŒŒė²„ ģŗ”ģ„œ ģøģŠ¤ķ‹°ķŠœķŠø ģøķ¬. ģ•”ģ˜ ģ¹˜ė£Œė„¼ ģœ„ķ•œ mica/b ģ•ŒķŒŒ 3 ė„ė©”ģøģ˜ ė°±ģ‹ ģ ‘ģ¢…
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
TWI709647B (zh) 2016-01-19 2020-11-11 ē¾Žå•†č¼ē‘žč‚”ä»½ęœ‰é™å…¬åø ē™Œē—‡ē–«č‹—
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3474890A1 (en) * 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
KR102437120B1 (ko) 2016-08-05 2022-08-25 ģ‚¬ė…øķ”¼ ķŒŒģŠ¤ķ‡“ė„“ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
JP7001686B2 (ja) 2016-08-05 2022-02-04 ć‚µćƒŽćƒ•ć‚£ ćƒ‘ć‚¹ćƒ„ćƒ¼ćƒ« ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ 多侔č‚ŗē‚ŽēƒčŒå¤šē³–体ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆēµ„ęˆē‰©
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
KR102622188B1 (ko) 2016-10-07 2024-01-05 ģ—”ķ„°ė”¬ ģ—ģŠ¤.ģ—ģ“. ģ•” ģ¹˜ė£Œė„¼ ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ķ™”ķ•©ė¬¼
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102101879B1 (ko) * 2017-03-15 2020-05-29 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
CN110662557A (zh) 2017-03-31 2020-01-07 č‘›å…°ē“ å²å…‹ēŸ„čƆäŗ§ęƒå¼€å‘ęœ‰é™å…¬åø 免ē–«åŽŸę€§ē»„合ē‰©ć€ē”Øé€”å’Œę²»ē–—ę–¹ę³•
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacƔridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
JP2020530478A (ja) 2017-08-14 2020-10-22 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åæœē­”ć‚’å¼·åŒ–ć™ć‚‹ę–¹ę³•
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
TWI725359B (zh) 2017-12-06 2021-04-21 ē¾Žå•†é»˜ę²™ę±č—„å»  包含č‚ŗē‚ŽéˆēƒčŒå¤šé†£-蛋ē™½ēµåˆē‰©ä¹‹ēµ„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
KR20230008923A (ko) 2018-02-05 2023-01-16 ģ‚¬ė…øķ”¼ ķŒŒģŠ¤ķ‡“ė„“ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¤ź°€ ķė “źµ¬ź· ģ„± ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CN112118863B (zh) 2018-04-11 2025-05-30 ꁩē‰¹ē½—姆公åø ē”ØäŗŽé¢„é˜²å’Œę²»ē–—ē™Œē—‡ēš„ęŠ—åŽŸč‚½
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
JP2021522213A (ja) 2018-04-18 2021-08-30 ć‚Øć‚¹ć‚±ćƒ¼ 惐悤ć‚Ŗ悵悤ć‚Øćƒ³ć‚¹ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ćƒŖ惟惆惃惉 ć‚¹ćƒˆćƒ¬ćƒ—ćƒˆć‚³ćƒƒć‚«ć‚¹ćƒ»ćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒ‹ć‚ØčŽ¢č†œå¤šē³–é”žåŠć³ćć®å…ē–«åŽŸę€§ęŽ„合体
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CA3129425A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
EP3965826A1 (en) 2019-05-10 2022-03-16 GlaxoSmithKline Biologicals S.A. Conjugate production
AU2020325569B2 (en) 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
CA3148924A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
ES2971929T3 (es) 2019-11-15 2024-06-10 Enterome S A PĆ©ptidos antigĆ©nicos para la prevenciĆ³n y el tratamiento de la neoplasia maligna de linfocitos B
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
NZ790372A (en) 2020-02-23 2026-01-30 Pfizer Escherichia coli compositions and methods thereof
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķė “źµ¬ź·  ė°±ģ‹ ģ— ģ‚¬ģš©ķ•˜źø° ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
JP7804673B2 (ja) 2020-11-10 2026-01-22 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć•ć›ćŸčŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
JP2024510717A (ja) 2021-02-22 2024-03-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©ć€ä½æē”ØåŠć³ę–¹ę³•
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
CN119317445A (zh) 2022-05-11 2025-01-14 č¾‰ē‘žå…¬åø ē”ØäŗŽē”Ÿäŗ§å«ęœ‰é˜²č…å‰‚ēš„ē–«č‹—制剂ēš„ę–¹ę³•
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć•ć›ćŸčŽ¢č†œē³–é”žęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
EP4694921A1 (en) 2023-04-14 2026-02-18 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4701656A1 (en) 2023-04-24 2026-03-04 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 ē¾Žå•†č¼ē‘žč‚”ä»½ęœ‰é™å…¬åø 包含ē¶“å…±č»›ä¹‹å¤§č…øę”æ菌ē³–ēš„免ē–«åŽŸę€§ēµ„ęˆē‰©åŠå…¶ē”Ø途
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2121481C1 (ru) * 1988-12-16 1998-11-10 Š”Šµ Š”тŠ°Ń‚ Š”ŠµŃ€ ŠŠµŠ“ŠµŃ€Š»Š°Š½Š“ŠµŠ½ Š’ŠµŃ€Ń‚ŠµŠ³ŠµŠ½Š²Š¾Ń€Š“ŠøŠ³Š“ Š”Š¾Ń€ Š“Šµ ŠœŠøŠ½Šøстр Š’Š°Š½ Š’ŠµŠ»Š·ŠµŠ¹Š½, Š’Š¾Š»ŠŗсŠ³ŠµŠ·Š¾Š½Š“хŠµŠ¹Š“ эŠ½ ŠšŃŽŠ»Ń‚ŃŽŃ€ ŠœŠ¾Š“ŠøфŠøцŠøрŠ¾Š²Š°Š½Š½Ń‹Š¹ ŠæŠ½ŠµŠ²Š¼Š¾Š»ŠøŠ·ŠøŠ½, рŠµŠŗŠ¾Š¼Š±ŠøŠ½Š°Š½Ń‚Š½Š°Ń ŠæŠ»Š°Š·Š¼ŠøŠ“Š°, сŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Š¼Š¾Š“ŠøфŠøцŠøрŠ¾Š²Š°Š½Š½Š¾Š³Š¾ ŠæŠ½ŠµŠ²Š¼Š¾Š»ŠøŠ·ŠøŠ½Š°, Š²Š°ŠŗцŠøŠ½Š°
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog VaccineprƦparat indeholdende adjuvanser
EP0618813B1 (en) * 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
WO1996032963A1 (en) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
CZ394297A3 (cs) 1995-06-07 1998-04-15 Biochem Vaccines Inc. StreptokokovĆ© proteiny teplotnĆ­ho Å”oku ze skupiny HSP70
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein eļæ½leniļæ½i iļæ½eren aļæ½ļæ½.
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
CA2292838A1 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
JP2001510031A (ja) 1997-07-21 2001-07-31 ćƒŽćƒ¼ć‚¹ćƒ»ć‚¢ćƒ”ćƒŖć‚«ćƒ³ćƒ»ćƒ“ć‚”ć‚Æć‚·ćƒ³ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ ćƒÆć‚Æćƒćƒ³ćØ恗恦恮äæ®é£¾ć•ć‚ŒćŸå…ē–«åŽŸćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒŖć‚·ćƒ³ēµ„ęˆē‰©
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
JP2004505885A (ja) 1998-08-19 2004-02-26 ćƒŽćƒ¼ć‚¹ć€€ć‚¢ćƒ”ćƒŖć‚«ćƒ³ć€€ćƒÆć‚Æćƒćƒ³ļ¼Œć€€ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼®āˆ’ć‚¢ć‚ÆćƒŖćƒ­ć‚¤ćƒ«åŒ–ćƒćƒŖć‚µćƒƒć‚«ćƒŖ惉悒ē”Ø恄恦ē”£ē”Ÿć•ć‚ŒćŸćƒÆć‚Æćƒćƒ³ćØć—ć¦ęœ‰ē”ØćŖ免ē–«åŽŸę€§Ī²āˆ’ćƒ—ćƒ­ćƒ”ć‚Ŗćƒ³ć‚¢ćƒŸćƒ‰é€£ēµćƒćƒŖć‚µćƒƒć‚«ćƒŖ惉āˆ’ć‚æćƒ³ćƒ‘ć‚Æč³Ŗēµåˆä½“
ES2322306T3 (es) * 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
CZ301445B6 (cs) 2010-03-03
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
HU229968B1 (hu) 2015-03-30
HU228499B1 (en) 2013-03-28
JP2011057713A (ja) 2011-03-24
CN1351501A (zh) 2002-05-29
CZ303653B6 (cs) 2013-01-30
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
EP1880735A2 (en) 2008-01-23
TWI286938B (en) 2007-09-21
PL355180A1 (en) 2004-04-05
MY125202A (en) 2006-07-31
US9168313B2 (en) 2015-10-27
DE60038166T2 (de) 2009-03-12
JP2002539273A (ja) 2002-11-19
AU3813600A (en) 2000-10-09
AR022964A1 (es) 2002-09-04
US8926985B2 (en) 2015-01-06
NO330532B1 (no) 2011-05-09
NO2011014I1 (no) 2011-09-19
EP1880735A3 (en) 2008-03-12
HK1043731B (en) 2009-01-23
IL145044A0 (en) 2002-06-30
KR100642044B1 (ko) 2006-11-10
CN1351503A (zh) 2002-05-29
JP4846906B2 (ja) 2011-12-28
JP5551579B2 (ja) 2014-07-16
FR10C0008I2 (fr) 2012-10-26
ES2300255T3 (es) 2008-06-16
BRPI0009163B1 (pt) 2019-04-09
CA2366314A1 (en) 2000-09-28
BE1025464I2 (2) 2019-03-06
MY125387A (en) 2006-07-31
CN1192798C (zh) 2005-03-16
KR100798212B1 (ko) 2008-01-24
DK1162999T3 (da) 2007-03-26
WO2000056358A2 (en) 2000-09-28
WO2000056358A3 (en) 2001-01-04
NZ513840A (en) 2004-02-27
EP1162998B1 (en) 2010-03-03
TWI235064B (en) 2005-07-01
DE122009000054I1 (de) 2009-12-31
US20110217329A1 (en) 2011-09-08
EP1162999B1 (en) 2006-11-29
DE60032120T2 (de) 2007-09-20
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
TR200102736T2 (tr) 2002-04-22
WO2000056360A2 (en) 2000-09-28
ATE387214T1 (de) 2008-03-15
KR20020000549A (ko) 2002-01-05
CY2009014I1 (el) 2010-07-28
HUS1500040I1 (hu) 2018-05-28
NZ513841A (en) 2001-09-28
CY1107561T1 (el) 2013-03-13
NO20014325L (no) 2001-11-14
TWI281403B (en) 2007-05-21
CZ20013379A3 (cs) 2002-03-13
NO20014325D0 (no) 2001-09-05
US20060002961A1 (en) 2006-01-05
EP2277535A3 (en) 2011-03-09
KR20020000785A (ko) 2002-01-05
NO330736B1 (no) 2011-06-27
CZ20013378A3 (cs) 2002-03-13
PL355264A1 (en) 2004-04-05
HUP0200373A2 (en) 2002-06-29
PT1162999E (pt) 2007-02-28
HUP0200367A2 (en) 2002-05-29
EP1162998A2 (en) 2001-12-19
US20150079125A1 (en) 2015-03-19
CY2009014I2 (el) 2010-07-28
US20050031646A1 (en) 2005-02-10
ES2339737T3 (es) 2010-05-25
AR022965A1 (es) 2002-09-04
AU750788B2 (en) 2002-07-25
US20060093626A1 (en) 2006-05-04
CA2366314C (en) 2012-01-10
TR200102735T2 (tr) 2002-04-22
EP2277535A2 (en) 2011-01-26
EP1776962A1 (en) 2007-04-25
EP1162999A2 (en) 2001-12-19
NO20014323L (no) 2001-11-14
BR0009163A (pt) 2001-12-26
IL145043A (en) 2007-06-17
KR20020001785A (ko) 2002-01-09
JP2002540074A (ja) 2002-11-26
DE60038166D1 (de) 2008-04-10
NO20014323D0 (no) 2001-09-05
WO2000056359A2 (en) 2000-09-28
HK1043731A1 (en) 2002-09-27
HK1043730A1 (zh) 2002-09-27
LU91652I2 (fr) 2010-10-13
AU3291900A (en) 2000-10-09
US20100119544A1 (en) 2010-05-13
AU750913B2 (en) 2002-08-01
NL300415I1 (nl) 2009-12-01
CA2365296A1 (en) 2000-09-28
MXPA01009452A (es) 2002-08-06
BRPI0009163B8 (pt) 2021-05-25
IL145045A0 (en) 2002-06-30
PL204890B1 (pl) 2010-02-26
AU750762B2 (en) 2002-07-25
JP2002540075A (ja) 2002-11-26
DE60043930D1 (de) 2010-04-15
HK1043728A1 (en) 2002-09-27
ATE346608T1 (de) 2006-12-15
HK1043728B (en) 2007-06-22
IL145043A0 (en) 2002-06-30
NZ513842A (en) 2004-05-28
DK1163000T3 (da) 2008-04-28
CY1107390T1 (el) 2010-07-28
FR10C0008I1 (fr) 2010-03-26
NO20014322L (no) 2001-11-14
TR200102739T2 (tr) 2001-12-21
BR0009154A (pt) 2001-12-26
BR0009166A (pt) 2001-12-26
HUP0200664A2 (en) 2002-06-29
AU3430700A (en) 2000-10-09
ATE459373T1 (de) 2010-03-15
US20030147922A1 (en) 2003-08-07
PL203917B1 (pl) 2009-11-30
AR022963A1 (es) 2002-09-04
PL355178A1 (en) 2004-04-05
NO20014322D0 (no) 2001-09-05
SI1162999T1 (sl) 2007-04-30
CN1391481A (zh) 2003-01-15
EP1163000A2 (en) 2001-12-19
NO2011014I2 (no) 2011-08-30
DE60032120D1 (de) 2007-01-11
WO2000056360A3 (en) 2001-01-25
WO2000056359A3 (en) 2001-02-01
SI1163000T1 (sl) 2008-06-30
IL145044A (en) 2007-03-08
EP1163000B1 (en) 2008-02-27
LU91652I9 (2) 2019-01-03
CN1191852C (zh) 2005-03-09

Similar Documents

Publication Publication Date Title
BE1025464I2 (2)
JP2002514480A5 (2)
BRPI0017527B8 (2)
IN2001KO01233A (2)
JP2002521141A5 (2)
JP2002521591A5 (2)
BRPI0001672A2 (2)
JP2002517184A5 (2)
JP2002519925A5 (2)
JP2002513244A5 (2)
JP2002506962A5 (2)
BRPI0001542A2 (2)
JP2002521163A5 (2)
JP2002513606A5 (2)
JP2002502016A5 (2)
BRPI0012675B8 (2)
JP2002522346A5 (2)
BRPI0017522A2 (2)
HU0004772D0 (2)
BRPI9917761A2 (2)
BRMU7902607U2 (2)
BRPI0303609A (2)
FI4323U1 (2)
JP2001182743A5 (2)
IN190455B (2)